marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits doxazosin tab binding of norepinephrine to alpha receptors in the autonomic nervous system. The primary effect of this blockage is relaxed vascular smooth muscle tone (vasodilation), which doxazosin tab peripheral vascular resistance.

?Legal status ? Prescription onlyRoutes doxazosin tab mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign doxazosin tab hyperplasia.On February 22, 2005, the US FDA approved a doxazosin tab release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and doxazosin tab prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure doxazosin tab benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to doxazosin tab marketed as Cardura® XL.It is an alpha blocker used to treat doxazosin tab doxazosin tab pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form doxazosin tab doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker.

number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475.